US Drug Pricing Legislation Efforts Headed Toward Spring Renewal? A Look Ahead
Senate legislation taking aim at price increases faces uphill climb, but sponsors are hoping President Trump will mobilize more support among congressional Republicans in the coming year.
You may also be interested in...
Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry.
Nearly $70bn in savings over 10 years is expected to result from mandatory price inflation rebates for drugs covered by Medicare Part D.
The new payment demonstration in Part D reflects the increasing recognition that insurance benefit design has a major impact on insulin affordability.